Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-06-27
2006-06-27
Richter, Johann (Department: 1621)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S365000, C514S372000, C514S374000, C514S396000, C514S709000, C546S272100, C546S339000, C548S200000, C548S214000, C548S215000, C548S338100, C549S078000, C564S123000, C568S031000
Reexamination Certificate
active
07067538
ABSTRACT:
The present invention relates to sulfones that are useful in the treatment of chemokine-mediated disorders. In certain embodiments, the present invention concerns the compounds that are MCP-1 receptor antagonists.
REFERENCES:
patent: 5183729 (1993-02-01), Naito et al.
patent: 5321000 (1994-06-01), Brannigan et al.
patent: WO 99/26615 (1999-06-01), None
patent: WO 01/07424 (2001-02-01), None
patent: WO 0/2060859 (2002-08-01), None
Springer, Timothy A., Nature, 1990, vol. 346, pp. 425-434.
Lawrence, Michael B. et al., Cell, vol. 65, 859-873, May 31, 1991.
Butcher, Eugene C., Cell, vol. 67, pp. 1033-1036, Dec. 20, 1991.
Ernst, C.A. et al., J. Immunol., 1994;152:(3541-3544).
Spangrude et al. J. Immunol. 1985;135(6):4135-4143.
Nourshargh and Williams J. Immunol. 1990;145(8):(2633-2638).
Sekido et al., Nature 1993;365(6447):654-657.
Hechtman et al. J. Immunol. 1991;147(3):883-892.
Huber et al., Science 1991;254(5028):99-102.
Carr et al. Proc. Natl. Acad. Sci. USA. 1994;91(9):3652-3656.
Kice J.L. and Rudzinski J.J., J. Am. Chem. Soc. 1987;109:2414.
Klenk M.M.; Suter C.M., Archer S., JACS 1948;70:3846.
McKennis, H. et al., JOC, 1963;28:383.
Heffner R.J. et al., Synth. Commun. 1991;21,2231-2256.
Khurana J.M. et al. G.C. J. Chem. Soc. Perkin Trans, 1996;1:2213.
Carceller E. et al., J. Med. Chem. 1993;36:2984.
Babu S.D. et al., Can. J. Chem. 1989;67:1071.
Dhainaut A. et al., J. Med. Chem. 2000;43:2165-2175.
Newman, J. Org. Chem. 1948;13:592.
Edwards. J. Org. Chem. 1964;29:913.
Olah, Synthesis 1984:228.
Hlasta, Tetrahedron Lett. 1989;vol. 30 No. 14:1773-76.
Nahm, Tetrahedron Lett. 1981;22:3815.
Ogura F., et al., Bull. Chem. Soc. Jpn 1983;56:1257-1258.
Wissner A. J., Org. Chem. 1979;44:4617-4622.
Langer P. et al., Syn. Lett. 2000;6:844-846.
Hirschmann R., J. Org. Chem. 2000;65:8307-8316.
Grossert J.S. et al., Can. J. Chem. 1984;62:798.
Kiyoaki K., et al. Bioorg. Med. Chem. Lett. 1996;6:2601-2606.
Abdel-Magid A.F. et al., J. Org. Chem. 1996;61:3849-3862.
Malinka W., Pol. J. Chem. 1995;69:95-102.
Ikechukwu I. Ekekezie, et al., Pediatric Research, vol. 50, No. 5, 2001 pp. 633-640.
Gibson J.A. et al., Can J. Chem. 1975;53:3044-3052.
Domenico et al., Synthesis 1994:34-36.
Kraynack and Pedersen JOC 1993;58(22); 6114-6117).
Schmidt et al., Synthesis 1987:896.
Berge S.M. et al., Pharmaceutical Salts. J. Pharma. Sci. 1977:66:1.
Fukuda, Yakugaku Zasshi 1952;72:1472.
Chem. Abstr., 1953:8706.
Bennett G.A., et al., Eur. J. Med. Chem., 1989;24:579.
Bagli J. F., Ferdinandi E. Can J. Chem., 1975;53:2598.
Huang, De Ren et al., J. Exp. Med, vol. 193, No. 6, Mar. 19, 2001 pp. 713-725.
Izikson, Leonid et al., J. Exp. Med, vol. 192, No. 7, Oct. 2, 2000 pp. 1075-1080.
Yuan, Guo-Hua et al., Arthritis & Rheumatism, vol. 44, No. 5, May 2001, pp. 1056-1070.
PCT Search Report PCT/IB/03186.
Sacca R et al., “Mediators of inflammation” Current Opinion In Immunology, Currrent Biology, Vo.l. 9, No. 6, Dec. 1997 pp. 851-857, XP004331462.
Bright C et al., “Identification Of A Non Peptidic Rantes Antagonist” Bioorganic & Medicinal Chemistry Letters, vol. 8, No. 7, Apr. 7, 1998 pp. 771-774, XP004136963.
Bratton Larry D.
Bridges Alexander J.
Connor David T.
Miller Steven R.
Song Yuntao
Ashbrook Charles W.
Nwaonicha Chukwuma
Richter Johann
Sherwood Michelle A.
Warner-Lambert Company LLC
LandOfFree
MCP-1 receptor antagonists and methods of use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with MCP-1 receptor antagonists and methods of use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and MCP-1 receptor antagonists and methods of use thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3687378